Ind-Swift Ltd

Ind-Swift Ltd Share Price Today: Live Updates & Key Insights

Get insights on Ind-Swift Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Ind-Swift Ltd Share Price Chart

Ind-Swift Ltd Fundamentals

Traded Volume: 6,45,158

Market Cap(Cr): 85

Avg Traded Price 15.15

1 Year return -36.48%

Upper Circuit 17.8

Lower Circuit 15.2

P/E TTM 0.00

P/B Ratio 52.00

Traded Value(Cr) 101.68

EPS TTM 52.331

Book value 52.331

Dividend 0.00%

Ind-Swift Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Ind-Swift Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Ind-Swift Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -3.67%

1M -4.31%

3M +21.89%

1Y -36.48%

YTD -55.34%

Ind-Swift Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Ind-Swift Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 74513.00

Day Before Yesterday 57870.00

1W Avg null

1M Avg null

3M Avg 1.69L

Ind-Swift Ltd Technical Details

Ind-Swift Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 15

Support 2 14

Support 3 12

Pivot Point : 16

Resistance 1 17

Resistance 2 19

Resistance 3 20

Ind-Swift Ltd Corporate Actions

Ind-Swift Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Ind-Swift Ltd’s capital allocation strategies.

All

Ex-Date 21-Sep-2011 Type D Description 0.40/share@20.00% Record Date 07-Nov-2025 Ratio 20.00

Ex-Date 24-Sep-2010 Type D Description 0.40/share@20.00% Record Date 07-Nov-2025 Ratio 20.00

Ex-Date 17-Sep-2009 Type D Description 0.40/share@20.00% Record Date 07-Nov-2025 Ratio 20.00

Ex-Date 19-Sep-2008 Type D Description 0.40/share@20.00% Record Date 07-Nov-2025 Ratio 20.00

Ex-Date 21-Sep-2007 Type D Description 2.00/share@20.00% Record Date 07-Nov-2025 Ratio 20.00

Dividends

Announcement Date 21-Sep-2011 Ex Dividend Date 21-Sep-2011 Dividend(%) 20

Announcement Date 24-Sep-2010 Ex Dividend Date 24-Sep-2010 Dividend(%) 20

Announcement Date 17-Sep-2009 Ex Dividend Date 17-Sep-2009 Dividend(%) 20

Announcement Date 19-Sep-2008 Ex Dividend Date 19-Sep-2008 Dividend(%) 20

Announcement Date 21-Sep-2007 Ex Dividend Date 21-Sep-2007 Dividend(%) 20

Bonus

No Bonus has been declared by INDSWFTLTD

Splits

No Split has been declared by INDSWFTLTD

Others

Rights No Rights has been declared by INDSWFTLTD

Ind-Swift Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Ind-Swift Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Ind-Swift Ltd's relative performance and valuation against major competitors.

Ind-Swift Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Ind-Swift Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 15.86 Mar 2024 15.28 Mar 2023 73.05 Mar 2022 89.63 Mar 2021 77.24

PARTICULARS Investing Activities Mar 2025 3.23 Mar 2024 76.61 Mar 2023 -29.34 Mar 2022 -18.42 Mar 2021 -16.71

PARTICULARS Financing Activities Mar 2025 -12.71 Mar 2024 -42.08 Mar 2023 -46.56 Mar 2022 -84.02 Mar 2021 -48.30

PARTICULARS Net Cash Flow Mar 2025 6.37 Mar 2024 49.81 Mar 2023 -2.85 Mar 2022 -12.81 Mar 2021 12.23

Ind-Swift Ltd Shareholding Pattern

This shows the ownership breakdown of Ind-Swift Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 55.58%

Public 44.42%

Other Institutions 0%

FII null%

Mutual Funds null%

About Ind-Swift Ltd

Ind-Swift Limited (ISL) is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.Ind-Swift Limited was incorporated in June, 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates.In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care.In the year 2000, the company launched Super Specialty Division, which is focusing on Cardiology and Diabetology segments. In the year 2001, they launched Pioglitazone and Candesartan, in which the company is the second to launch this product in India. In addition, they launched Institution/Hospital Division.In the year 2003, the company launched another division by the name Ind-Swift Biosciences. They entered into formulations export to six countries and filed patent in US for Clarithromycin.In the year 2004, the company launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT. They launched Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials. In addition, they launched another division by the name Resurgence catering to the Anesthesiology and Oncology segments. The company opened first overseas office in New Jersey, USADuring the year 2004-05, the company launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia. They commenced commercial production in their new formulation facility at Jammu, J&K. During the year 2005-06, the company introduced various new product ranges in the domestic market through their nine marketing divisions. The new product launches included the launch of a unique combination of the Quinoline derivative, anti-diarrheal and anti-bacterial drug that was launched for the first time in India after completion of the successful clinical trials. They also launched the new marketing division namely Institutions & Hospitals division to look after the institutional sales. During the year, the company commissioned three new state of the art finished dosages facility at; Samba in Jammu & Kashmir; 100% EOU at Jawaharpur and an internationally benchmarked plant at Baddi in Himachal Pradesh.During the year 2006-07, the company developed and launched 65 new products and line extension. They launched their product in Kenya and Senegal. They also launched three new marketing division to focus on marketing of products for personal healthcare, veterinary and manufacturing and marketing of products for international companies.During the year, the company entered into licensing agreements with number of international Pharma companies for out licensing the technology of their patented products, Clarithromycin. They received approval of the Drug Authorities of Uganda and Tanzania, which will pave the way for the supply of their drugs in these countries.During the year 2007-08, the company's manufacturing unit at Parwanoo was upgraded as per WHO standards. The Global Business Unit (ISL-GBU), commissioned in Derabassi. In August 2007, the company commissioned a manufacturing facility at the same tax exempted zone and green plains of Baddi. This facility is for soft Gelatin Encapsultation with an annual capacity of 36 crore. In December 2007, they launched their new division Diagnozis dealing in medical equipments & devices. The company also launched animal health care, which is absolutely a new concept with outsourced marketing.Company launched a new marketing division 'NOVA' with special focus on ophthalmology, ENT and Dermatology in 2009-10.During 2010-11, the Company launched six divisions viz GENERIC, ONCRIT, MEGASWIFT, GYNOSWIFT, Q-DEN and CARDIA SWIFT. Apart from this, it launched new product range in all the new divisions including monopolistic products. During 2012, the Company diversified into the Dairy Business by launching a new division, which marketed under the brand name All Natural.In 2021, company established a separate OTC division and launched 2 products via, Stevia and Hangover.In 2022-23, Company launched many new products such as Linezolid, Ticagrelor, Etoricoxib, and Diclofenac Hot gel and Four Derm ointment etc. Also , Company set up its first wholly owned subsidiary in the Republic of Kenya with the name of `Indswift India Limited' in May, 2022. Further, Company also launched new products like Metalazone, Lenalidomide Anhydrous and Methotrexate in the domestic market in 2024.

Managing Director & CEO

G Munjal

Registered office 781 Industrial Area Phase-II, Ram Darbar, Chandigarh, Chandigarh, 160002

FAX :91-0172-2638781-786

Background

Incorporation Year 1986

Face Value ₹2.00

Market Lot 1

Ind-Swift Ltd Latest News

VIEW MORE NEWS

FAQs on Ind-Swift Ltd